In BRCA‐deficient or PARPi‐resistant tumours, CHK1 inhibitors such as prexasertib enhance PARPi efficacy by destabilising stalled forks and aggravating replication‐associated DNA damage.100. Here, CHEK1 is linked to neoplasm.